keyword
https://read.qxmd.com/read/37699232/removal-of-gemcitabine-induced-senescent-cancer-cells-by-targeting-glutaminase1-improves-the-therapeutic-effect-in-pancreatic-ductal-adenocarcinoma
#21
JOURNAL ARTICLE
Keisuke Oyama, Yoshifumi Iwagami, Shogo Kobayashi, Kazuki Sasaki, Daisaku Yamada, Yoshito Tomimaru, Takehiro Noda, Tadafumi Asaoka, Hidenori Takahashi, Masahiro Tanemura, Yuichiro Doki, Hidetoshi Eguchi
Insufficient cancer treatment can induce senescent cancer cell formation and treatment resistance. The characteristics of induced senescent cancer (iSnCa) cells remain unclear. Pancreatic ductal adenocarcinoma (PDAC) has a low and nondurable response rate to current treatments. Our study aimed to analyze the properties of iSnCa cells and the relationship between cellular senescence and prognosis in PDAC. We evaluated the characteristics of gemcitabine-induced senescent cancer cells and the effect of senescence-associated secretory phenotype (SASP) factors released by iSnCa cells on surrounding PDAC cells...
September 12, 2023: International Journal of Cancer. Journal International du Cancer
https://read.qxmd.com/read/37696420/canagliflozin-reduces-chemoresistance-in-hepatocellular-carcinoma-through-pkm2-c-myc-complex-mediated-glutamine-starvation
#22
JOURNAL ARTICLE
Yuan Zeng, Haoran Jiang, Xiangting Zhang, Jun Xu, Xiao Wu, Qian Xu, Weimin Cai, Huiya Ying, Ruoru Zhou, Yingrong Ding, Kanglei Ying, Xian Song, Zhuoyan Chen, Liuwei Zeng, Luying Zhao, Fujun Yu
Cisplatin (CPT) is one of the standard treatments for hepatocellular carcinoma (HCC). However, its use is limits as a monotherapy due to drug resistance, and the underlying mechanism remains unclear. To solve this problem, we tried using canagliflozin (CANA), a clinical drug for diabetes, to reduce chemoresistance to CPT, and the result showed that CANA could vigorously inhibit cell proliferation and migration independent of the original target SGLT2. Mechanistically, CANA reduced aerobic glycolysis in HCC by targeting PKM2...
September 9, 2023: Free Radical Biology & Medicine
https://read.qxmd.com/read/37679553/glutaminase-gls1-gene-expression-in-primary-breast-cancer
#23
JOURNAL ARTICLE
Neelima Vidula, Christina Yau, Hope S Rugo
BACKGROUND: Tumor growth is mediated in part by glutamine, and glutaminase is an enzyme necessary for glutamine catabolism. We studied glutaminase (GLS1) gene expression in primary breast cancer to determine correlations with clinical and tumor characteristics, and gene associations in publicly available databases. A better understanding of glutaminase gene expression may help guide further exploration of glutaminase inhibitors in breast cancer. METHODS: GLS1 mRNA levels were evaluated in The Cancer Genome Atlas (n = 817) and METABRIC (n = 1992) datasets...
November 2023: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://read.qxmd.com/read/37627015/metabolic-heterogeneity-plasticity-and-adaptation-to-glutamine-addiction-in-cancer-cells-the-role-of-glutaminase-and-the-gt%C3%AF-a-glutamine-transaminase-%C3%AF-amidase-glutaminase-ii-pathway
#24
REVIEW
Arthur J L Cooper, Thambi Dorai, John T Pinto, Travis T Denton
Many cancers utilize l-glutamine as a major energy source. Often cited in the literature as "l-glutamine addiction", this well-characterized pathway involves hydrolysis of l-glutamine by a glutaminase to l-glutamate, followed by oxidative deamination, or transamination, to α-ketoglutarate, which enters the tricarboxylic acid cycle. However, mammalian tissues/cancers possess a rarely mentioned, alternative pathway (the glutaminase II pathway): l-glutamine is transaminated to α-ketoglutaramate (KGM), followed by ω-amidase (ωA)-catalyzed hydrolysis of KGM to α-ketoglutarate...
August 14, 2023: Biology
https://read.qxmd.com/read/37610850/enhancing-the-affinity-of-novel-gls1-allosteric-inhibitors-by-targeting-key-residue-lys320
#25
JOURNAL ARTICLE
Li Zhu, Xiujin Chang, Shengpeng Zhang, Xiumei Bai, Alexander V Finko, Xi Xu, Jinlei Bian, Xiaoping Liu, Huidan Huang
Aim: A series of novel GLS1 irreversible allosteric inhibitors targeting Lys320 might have robust enzyme inhibitory activity and potent antitumor activity. Materials & methods: Novel GLS1 allosteric inhibitors targeting Lys320 were synthesized and their anticancer activity was assessed. Moreover, GLS1 protein was used as a model system to analyze the reactivity of these electrophilic groups in GLS1 irreversible allosteric inhibitors with other amino acids, including tyrosine, histidine, serine and threonine, using biochemical and biophysical assays...
August 23, 2023: Future Medicinal Chemistry
https://read.qxmd.com/read/37549852/design-and-structural-optimization-of-thiadiazole-derivatives-with-potent-gls1-inhibitory-activity
#26
JOURNAL ARTICLE
Takuya Okada, Kaho Yamabe, Michiko Jo, Yuko Sakajiri, Tomokazu Shibata, Ryusuke Sawada, Yoshihiro Yamanishi, Daisuke Kanayama, Hisashi Mori, Mineyuki Mizuguchi, Takayuki Obita, Yuko Nabeshima, Keiichi Koizumi, Naoki Toyooka
GLS1 is an attractive target not only as anticancer agents but also as candidates for various potential pharmaceutical applications such as anti-aging and anti-obesity treatments. We performed docking simulations based on the complex crystal structure of GLS1 and its inhibitor CB-839 and found that compound A bearing a thiadiazole skeleton exhibits GLS1 inhibition. Furthermore, we synthesized 27 thiadiazole derivatives in an effort to obtain a more potent GLS1 inhibitor. Among the synthesized derivatives, 4d showed more potent GLS1 inhibitory activity (IC50 of 46...
August 5, 2023: Bioorganic & Medicinal Chemistry Letters
https://read.qxmd.com/read/37541633/sirt4-protects-against-intestinal-fibrosis-by-facilitating-gls1-degradation
#27
JOURNAL ARTICLE
Xinru Xue, Xi Zeng, Xiaoqian Wu, Kexin Mu, Yue Dai, Zhifeng Wei
Intestinal fibrosis is a prevalent complication of Crohn's disease (CD), characterized by excessive deposition of extracellular matrix (ECM), and no approved drugs are currently available for its treatment. Sirtuin 4 (SIRT4), a potent anti-fibrosis factor in mitochondria, has an unclear role in intestinal fibrosis. In this study, fibroblasts isolated from biopsies of stenotic ileal mucosa in CD patients were analyzed to identify the most down-regulated protein among SIRT1-7, and SIRT4 was found to be the most affected...
August 2, 2023: Matrix Biology: Journal of the International Society for Matrix Biology
https://read.qxmd.com/read/37513875/the-glutaminase-1-inhibitor-11-c-carbony-bptes-synthesis-and-positron-emission-tomography-study-in-mice
#28
JOURNAL ARTICLE
Yiding Zhang, Katsushi Kumata, Lin Xie, Yusuke Kurihara, Masanao Ogawa, Tomomi Kokufuta, Nobuki Nengaki, Ming-Rong Zhang
Bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES) is a selective inhibitor of glutaminase-1 (GLS1), consequently inhibiting glutaminolysis. BPTES is known for its potent antitumor activity and plays a significant role in senescent cell removal. In this study, we synthesized [11 C-carbonyl]BPTES ([11 C]BPTES) as a positron emission tomography (PET) probe for the first time and assessed its biodistribution in mice using PET. [11 C]BPTES was synthesized by the reaction of an amine precursor () with [11 C-carbonyl]phenylacetyl acid anhydride ([11 C] 2 ), which was prepared from [11 C]CO2 and benzyl magnesium chloride, followed by in situ treatment with isobutyl chloroformate...
July 5, 2023: Pharmaceuticals
https://read.qxmd.com/read/37513376/atractylenolide-iii-ameliorates-bile-duct-ligation-induced-liver-fibrosis-by-inhibiting-the-pi3k-akt-pathway-and-regulating-glutamine-metabolism
#29
JOURNAL ARTICLE
Yan Wang, Kun Shi, Jiyuan Tu, Chang Ke, Niping Chen, Bo Wang, Yanju Liu, Zhongshi Zhou
Liver fibrosis is one of the leading causes of hepatic sclerosis and hepatocellular carcinoma worldwide. However, the complex pathophysiological mechanisms of liver fibrosis are unknown, and no specific drugs are available to treat liver fibrosis. Atractylenolide III (ATL III) is a natural compound isolated from the plant Atractylodes lancea (Thunb.) DC. that possesses antioxidant properties and the ability to inhibit inflammatory responses. In this study, cholestatic hepatic fibrosis was induced in mice using a bile duct ligation (BDL) model and treated with 10 mg/kg and 50 mg/kg of ATL III via gavage for 14 days...
July 19, 2023: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://read.qxmd.com/read/37434399/glutamine-metabolic-microenvironment-drives-m2-macrophage-polarization-to-mediate-trastuzumab-resistance-in-her2-positive-gastric-cancer
#30
JOURNAL ARTICLE
Xingbin Hu, Zhenfeng Ma, Beibei Xu, Shulong Li, Zhiqi Yao, Bishan Liang, Jiao Wang, Wangjun Liao, Li Lin, Chunling Wang, Siting Zheng, Qijing Wu, Qiong Huang, Le Yu, Fenghua Wang, Min Shi
BACKGROUND: Trastuzumab is a first-line targeted therapy for human epidermal growth factor receptor-2 (HER2)-positive gastric cancer. However, the inevitable occurrence of acquired trastuzumab resistance limits the drug benefit, and there is currently no effective reversal measure. Existing researches on the mechanism of trastuzumab resistance mainly focused on tumor cells themselves, while the understanding of the mechanisms of environment-mediated drug resistance is relatively lacking...
July 11, 2023: Cancer Communications
https://read.qxmd.com/read/37401237/regulation-of-glucose-and-glutamine-metabolism-to-overcome-cisplatin-resistance-in-intrahepatic-cholangiocarcinoma
#31
So Mi Yang, Jueun Kim, Ji-Yeon Lee, Jung-Shin Lee, Ji Min Lee
Intrahepatic cholangiocarcinoma (ICC) is one of the bile duct cancers and a rare malignant tumor with a poor prognosis owing to a lack of early diagnosis and resistance to conventional chemotherapy. A combination of gemcitabine and cisplatin is a treatment approach typically being attempted for the first line. However, its underlying mechanism of resistance to chemotherapy is poorly understood. We addressed this by studying the dynamics in the human ICC SCK cell line. Here, we report that the regulation of glucose and glutamine metabolism is a key factor in overcoming cisplatin resistance of SCK...
July 4, 2023: BMB Reports
https://read.qxmd.com/read/37384529/glutaminase-1-deficiency-confined-in-forebrain-neurons-causes-autism-spectrum-disorder-like-behaviors
#32
JOURNAL ARTICLE
Chenhui Ji, Yalin Tang, Yanyan Zhang, Xiaoyan Huang, Congcong Li, Yuhong Yang, Qihui Wu, Xiaohuan Xia, Qingyuan Cai, Xin-Rui Qi, Jialin C Zheng
An abnormal glutamate signaling pathway has been proposed in the mechanisms of autism spectrum disorder (ASD). However, less is known about the involvement of alterations of glutaminase 1 (GLS1) in the pathophysiology of ASD. We show that the transcript level of GLS1 is significantly decreased in the postmortem frontal cortex and peripheral blood of ASD subjects. Mice lacking Gls1 in CamKIIα-positive neurons display a series of ASD-like behaviors, synaptic excitatory and inhibitory (E/I) imbalance, higher spine density, and glutamate receptor expression in the prefrontal cortex, as well as a compromised expression pattern of genes involved in synapse pruning and less engulfed synaptic puncta in microglia...
June 28, 2023: Cell Reports
https://read.qxmd.com/read/37340070/exosomal-mir-381-from-m2-polarized-macrophages-attenuates-urethral-fibroblasts-activation-through-yap-gls1-regulated-glutaminolysis
#33
JOURNAL ARTICLE
Ye-Hui Chen, Yi-Cheng Xu, Ting-Ting Lin, Hang Chen, Ru-Nan Dong, Feng-Ping Cai, Zhi-Bin Ke, Jia-Yin Chen, Yong Wei, Qing-Shui Zheng, Xue-Yi Xue, Ning Xu
OBJECTIVE AND DESIGN: Post-traumatic urethral stricture is a clinical challenge for both patients and clinicians. Targeting glutamine metabolism to suppress excessive activation of urethral fibroblasts (UFBs) is assumed to be a potent and attractive strategy for preventing urethral scarring and stricture. MATERIAL OR SUBJECTS: In cellular experiments, we explored whether glutaminolysis meets the bioenergetic and biosynthetic demands of quiescent UFBs converted into myofibroblasts...
June 21, 2023: Inflammation Research: Official Journal of the European Histamine Research Society ... [et Al.]
https://read.qxmd.com/read/37267365/activation-of-piezo1-promotes-osteogenic-differentiation-of-aortic-valve-interstitial-cell-through-yap-dependent-glutaminolysis
#34
JOURNAL ARTICLE
Guoheng Zhong, Shuwen Su, Juncong Li, Hengli Zhao, Dongtu Hu, Jun Chen, Shichao Li, Yingwen Lin, Liming Wen, Xiangjie Lin, Gaopeng Xian, Dingli Xu, Qingchun Zeng
Hemodynamic overload and dysregulation of cellular metabolism are involved in development of calcific aortic valve disease (CAVD). However, how mechanical stress relates to metabolic changes in CAVD remains unclear. Here, we show that Piezo1, a mechanosensitive ion channel, regulated glutaminase 1 (GLS1)-mediated glutaminolysis to promote osteogenic differentiation of valve interstitial cells (VICs). In vivo, two models of aortic valve stenosis were constructed by ascending aortic constriction (AAC) and direct wire injury (DWI)...
June 2, 2023: Science Advances
https://read.qxmd.com/read/37263753/emodin-promotes-hepatic-stellate-cell-senescence-and-alleviates-liver-fibrosis-via-nur77-mediated-epigenetic-regulation-of-gls1
#35
JOURNAL ARTICLE
Li Chen, Baoyu Liang, Siwei Xia, Feixia Wang, Zhanghao Li, Jiangjuan Shao, Zili Zhang, Anping Chen, Shizhong Zheng, Feng Zhang
BACKGROUND AND PURPOSE: Senescence in hepatic stellate cells (HSCs) limits liver fibrosis. Glutaminolysis promotes HSC activation. We here investigated how emodin affected HSC senescence involving glutaminolysis. EXPERIMENTAL APPROACH: Senescence, glutaminolysis metabolites, Nur77 nuclear translocation, glutaminase 1 (GLS1) promoter methylation, and related signaling pathways were examined in human HSC-LX2 cells using multiple cellular and molecular approaches. Fibrotic mice with shRNA-mediated knockdown of Nur77 were treated with emodin-vitamin A liposome for investigating the mechanisms in vivo...
June 1, 2023: British Journal of Pharmacology
https://read.qxmd.com/read/37253167/exploration-of-imaging-biomarkers-for-metabolically-targeted-osteosarcoma-therapy-in-a-murine-xenograft-model
#36
JOURNAL ARTICLE
Shan Huang, Ling Ren, Jessica A Beck, Tim E Phelps, Colleen Olkowski, Anita Ton, Jyoti Roy, Margaret E White, Stephen Adler, Karen Wong, Aswini Cherukuri, Xiang Zhang, Falguni Basuli, Peter L Choyke, Elaine M Jagoda, Amy K LeBlanc
Background: Osteosarcoma (OS) is an aggressive pediatric cancer with unmet therapeutic needs. Glutaminase 1 (GLS1) inhibition, alone and in combination with metformin, disrupts the bioenergetic demands of tumor progression and metastasis, showing promise for clinical translation. Materials and Methods: Three positron emission tomography (PET) clinical imaging agents, [18 F]fluoro-2-deoxy-2-D-glucose ([18 F]FDG), 3'-[18 F]fluoro-3'-deoxythymidine ([18 F]FLT), and (2S, 4R)-4-[18 F]fluoroglutamine ([18 F]GLN), were evaluated, using the MG63...
May 29, 2023: Cancer Biotherapy & Radiopharmaceuticals
https://read.qxmd.com/read/37089092/-inhibition-of-glutaminolysis-alleviates-myocardial-fibrosis-induced-by-angiotensin-ii
#37
JOURNAL ARTICLE
Pan-Pan Wang, Hao-Miao Bai, Si-Yu He, Zi-Qi Xia, Mei-Jie Liu, Jiong An, Jia-Heng Zhou, Chen-Han Li, Wei Zhang, Xing Zhang, Xin-Pei Wang, Jia Li
The present study was aimed to investigate the role and mechanism of glutaminolysis of cardiac fibroblasts (CFs) in hypertension-induced myocardial fibrosis. C57BL/6J mice were administered with a chronic infusion of angiotensin II (Ang II, 1.6 mg/kg per d) with a micro-osmotic pump to induce myocardial fibrosis. Masson staining was used to evaluate myocardial fibrosis. The mice were intraperitoneally injected with BPTES (12.5 mg/kg), a glutaminase 1 (GLS1)-specific inhibitor, to inhibit glutaminolysis simultaneously...
April 25, 2023: Sheng Li Xue Bao: [Acta Physiologica Sinica]
https://read.qxmd.com/read/37032576/glutaminase-1-isoform-up-regulation-associated-with-lipid-metabolism-disorder-induced-by-methyl-tertiary-butyl-ether-in-male-rats
#38
JOURNAL ARTICLE
Mingxiao Guo, Mengdi Li, Li Chen, Hanyun Wang, Jiajia Wang, Piye Niu, Junxiang Ma
Methyl tertiary-butyl ether (MTBE) is a new unleaded gasoline additive, which is considered to be associated with abnormal lipid metabolism in many studies, but the metabolic characteristics and mechanism are still unclear. To observe the characteristics of lipid metabolism induced by MTBE and possible pathways, 21 male Wistar rats got intragastric administration for 24 weeks. The serum lipid metabolism indexes and metabolites were analyzed separately by a biochemical analyzer and untargeted metabolomics. And found that serum high-density lipoprotein cholesterol (HDL-C) levels in the exposure group were significantly reduced, and serum very low-density lipoprotein (VLDL) levels were significantly increased...
April 15, 2023: Ecotoxicology and Environmental Safety
https://read.qxmd.com/read/37011768/design-synthesis-structure-activity-relationship-studies-and-evaluation-of-novel-gls1-inhibitors
#39
JOURNAL ARTICLE
Michiko Jo, Keiichi Koizumi, Mizuho Suzuki, Daisuke Kanayama, Yurie Watanabe, Hiroaki Gouda, Hisashi Mori, Mineyuki Mizuguchi, Takayuki Obita, Yuko Nabeshima, Naoki Toyooka, Takuya Okada
Glutaminase converts glutamine into glutamic acid and has two isoforms: glutaminase 1 (GLS1) and glutaminase 2 (GLS2). GLS1 is overexpressed in several tumors, and research to develop glutaminase inhibitors as antitumor drugs is currently underway. The present study examined candidate GLS1 inhibitors using in silico screening and attempted to synthesize novel GLS1 inhibitors and assess their GLS1 inhibitory activities in a mouse kidney extract and against recombinant mouse and human GLS1. Novel compounds were synthesized using compound C as the lead compound, and their GLS1 inhibitory activities were evaluated using the mouse kidney extract...
April 1, 2023: Bioorganic & Medicinal Chemistry Letters
https://read.qxmd.com/read/36996714/targeting-glutaminase-1-gls1-by-small-molecules-for-anticancer-therapeutics
#40
REVIEW
Yangyang Chen, Lun Tan, Jing Gao, Congcong Lin, Fengbo Wu, Yang Li, Jifa Zhang
Glutaminase-1 (GLS1) is a critical enzyme involved in several cellular processes, and its overexpression has been linked to the development and progression of cancer. Based on existing research, GLS1 plays a crucial role in the metabolic activities of cancer cells, promoting rapid proliferation, cell survival, and immune evasion. Therefore, targeting GLS1 has been proposed as a promising cancer therapy strategy, with several GLS1 inhibitors currently under development. To date, several GLS1 inhibitors have been identified, which can be broadly classified into two types: active site and allosteric inhibitors...
March 23, 2023: European Journal of Medicinal Chemistry
keyword
keyword
106630
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.